Tirzepatide and health‐related quality of life in adults with obesity or overweight: Results from the SURMOUNT ‐3 phase 3 randomized trial
Authors' conclusion
Tirzepatide improved HRQoL in adults with obesity/overweight and was generally associated with larger improvements in adults meeting greater weight reduction thresholds and in adults with versus without reported physical function limitations at randomization.
Study context
- Population
- Adults with obesity/overweight who had achieved ≥5% weight reduction with a 12-week intensive lifestyle intervention
- Participants
- 287 vs 292
- Comparison
- Tirzepatide maximum tolerated dose vs placebo
- Tirzepatiden = 287
- Placebon = 292reference
- Primary endpoint
- HRQoL
- Follow-up
- Randomization to 72 weeks
Methodological detailsphase 3, double-blind, 72-week
- Phase 3
- Double-blind
- 72-week
Primary result
As reported in the abstract
- Tirzepatide associated with significantly larger improvements than placebo in most health-related quality of life (HRQoL) measures
- Trial primary endpoint: HRQoL (SF-36v2 acute, IWQOL-Lite-CT, EQ-5D-5L Health State Index, EQ VAS, Patient Global Impression of Status (PGIS) for Physical Activity), randomization to week 72
Further findings
HRQoL change in tirzepatide recipients by weight reduction thresholds · randomization to week 72
- Improvements generally numerically larger in those meeting greater weight reduction thresholds
HRQoL change in tirzepatide recipients with vs without physical function limitations at randomization · randomization to week 72
- Greater improvements with vs without physical function limitations for all measures
Original publication
Tirzepatide and health‐related quality of life in adults with obesity or overweight: Results from the SURMOUNT ‐3 phase 3 randomized trial. Diabetes Obes Metab. Published 14 May 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →